AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV cohort study

JAMA

Volumn 282, Issue 23, 1999, Pages 2220-2226

  Ledergerber, Bruno ^a   Egger, Matthias ^b   Erard, Véronique ^c   Weber, Rainer ^a   Hirschel, Bernard ^d   Furrer, Hansjakob ^e   Battegay, Manuel ^f   Vernazza, Pietro ^g   Bernasconi, Enos ^h   Opravil, Milos ^a   Kaufmann, Daniel ^c   Sudre, Philippe ^c   Francioli, Patrick ^c   Telenti, Amalio ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f KANTONSSPITAL BASEL   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; TOXOPLASMOSIS; TUBERCULOSIS;

EID: 0033572954     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.23.2220     Document Type: Article

References (32)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863-868.
3. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194-1199.
4. Michelet C, Arvieux C, François C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998;12:1815-1822.
5. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998;351:1682-1686.
6. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. AIDS. 1998;12:2115-2123.
7. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
8. Carr A, Cooper DA. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;350:589.
9. Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis. 1998;26:1008-1009.
10. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998;351:252-255.
11. Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol. 1998;116:169-175.
12. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1998;125:292-300.
13. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 1998;351:228-230.
14. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed. 1994;39:387-394.
15. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
16. Perry CM, Noble S. Saquinavir soft-gel capsule formulation: a review of its use in patients with HIV infection. Drugs. 1998;55:461-486.
17. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982; 69:239-241.
18. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. BMJ. 1999;319:23-24.
19. Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis. 1998;27:1510-1513.
20. Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis: treatment with corticosteroids. Am J Med. 1999; 106:371-372.
21. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130:570-577.
22. Feinberg J. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia [editorial]. Lancet. 1999;353:1287.
23. Chene G, Binquet C, Moreau JF, et al. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. AIDS. 1998;12:2313-2320.
24. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet. 1999;353:1293-1298.
25. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med. 1999; 340:1301-1306.
26. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-750.
27. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723-724.
28. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998; 280:1871-1873.
29. Hengge UR, Goos M, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS. 1998; 12:F225-F234.
30. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr. 1999;21:114-119.
31. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
32. Hirschel B, Francioli P. Progress and problems in the fight against AIDS. W Engl J Med. 1998;338:906-908.